ID   MTA1_HUMAN              Reviewed;         715 AA.
AC   Q13330; A5PLK4; Q86SW2; Q8NFI8; Q96GI8;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   22-SEP-2009, sequence version 2.
DT   28-JUN-2023, entry version 220.
DE   RecName: Full=Metastasis-associated protein MTA1;
GN   Name=MTA1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANT THR-612.
RX   PubMed=8083195; DOI=10.1016/s0021-9258(17)31603-4;
RA   Toh Y., Pencil S.D., Nicolson G.L.;
RT   "A novel candidate metastasis-associated gene, mta1, differentially
RT   expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA
RT   cloning, expression, and protein analyses.";
RL   J. Biol. Chem. 269:22958-22963(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANT THR-612.
RX   PubMed=7607577; DOI=10.1016/0378-1119(94)00410-t;
RA   Toh Y., Pencil S.D., Nicolson G.L.;
RT   "Analysis of the complete sequence of the novel metastasis-associated
RT   candidate gene, mta1, differentially expressed in mammary adenocarcinoma
RT   and breast cancer cell lines.";
RL   Gene 159:97-104(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND SUBCELLULAR LOCATION
RP   (ISOFORM SHORT).
RC   TISSUE=Mammary gland;
RX   PubMed=12167865; DOI=10.1038/nature00889;
RA   Kumar R., Wang R.-A., Mazumdar A., Talukder A.H., Mandal M., Yang Z.,
RA   Bagheri-Yarmand R., Sahin A., Hortobagyi G., Adam L., Barnes C.J.,
RA   Vadlamudi R.K.;
RT   "A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in
RT   the cytoplasm.";
RL   Nature 418:654-657(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG), AND VARIANT THR-612.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 10-299 (ISOFORM 3).
RC   TISSUE=Cervix carcinoma;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   IDENTIFICATION IN NURD COMPLEX.
RX   PubMed=9885572; DOI=10.1016/s1097-2765(00)80299-3;
RA   Xue Y., Wong J., Moreno G.T., Young M.K., Cote J., Wang W.;
RT   "NURD, a novel complex with both ATP-dependent chromatin-remodeling and
RT   histone deacetylase activities.";
RL   Mol. Cell 2:851-861(1998).
RN   [8]
RP   INTERACTION WITH ITGB3BP.
RX   PubMed=15254226; DOI=10.1128/mcb.24.15.6581-6591.2004;
RA   Talukder A.H., Gururaj A., Mishra S.K., Vadlamudi R.K., Kumar R.;
RT   "Metastasis-associated protein 1 interacts with NRIF3, an estrogen-
RT   inducible nuclear receptor coregulator.";
RL   Mol. Cell. Biol. 24:6581-6591(2004).
RN   [9]
RP   FUNCTION (ISOFORM SHORT), PHOSPHORYLATION BY CSNK1G2/CK1, INTERACTION WITH
RP   CSNK1G2, AND SUBCELLULAR LOCATION (ISOFORM SHORT).
RX   PubMed=15077195; DOI=10.1038/sj.onc.1207569;
RA   Mishra S.K., Yang Z., Mazumdar A., Talukder A.H., Larose L., Kumar R.;
RT   "Metastatic tumor antigen 1 short form (MTA1s) associates with casein
RT   kinase I-gamma2, an estrogen-responsive kinase.";
RL   Oncogene 23:4422-4429(2004).
RN   [10]
RP   INTERACTION WITH MBD3L2.
RX   PubMed=15701600; DOI=10.1074/jbc.m413492200;
RA   Jin S.-G., Jiang C.-L., Rauch T., Li H., Pfeifer G.P.;
RT   "MBD3L2 interacts with MBD3 and components of the NuRD complex and can
RT   oppose MBD2-MeCP1-mediated methylation silencing.";
RL   J. Biol. Chem. 280:12700-12709(2005).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-386 AND THR-564, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [13]
RP   FUNCTION, INTERACTION WITH EP300, SUBCELLULAR LOCATION (ISOFORM LONG),
RP   TISSUE SPECIFICITY, ACETYLATION AT LYS-626, AND MUTAGENESIS OF LYS-626.
RX   PubMed=16617102; DOI=10.1073/pnas.0601989103;
RA   Gururaj A.E., Singh R.R., Rayala S.K., Holm C., den Hollander P., Zhang H.,
RA   Balasenthil S., Talukder A.H., Landberg G., Kumar R.;
RT   "MTA1, a transcriptional activator of breast cancer amplified sequence 3.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:6670-6675(2006).
RN   [14]
RP   ERRATUM OF PUBMED:16617102.
RA   Gururaj A.E., Singh R.R., Rayala S.K., Holm C., den Hollander P., Zhang H.,
RA   Balasenthil S., Talukder A.H., Landberg G., Kumar R.;
RL   Proc. Natl. Acad. Sci. U.S.A. 110:4147-4148(2013).
RN   [15]
RP   FUNCTION, IDENTIFICATION IN THE NURD COMPLEX, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=16428440; DOI=10.1128/mcb.26.3.843-851.2006;
RA   Le Guezennec X., Vermeulen M., Brinkman A.B., Hoeijmakers W.A., Cohen A.,
RA   Lasonder E., Stunnenberg H.G.;
RT   "MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical
RT   and functional properties.";
RL   Mol. Cell. Biol. 26:843-851(2006).
RN   [16]
RP   FUNCTION, INTERACTION WITH HDAC2, ACETYLATION AT LYS-626, AND MUTAGENESIS
RP   OF LYS-626.
RX   PubMed=17671180; DOI=10.1158/0008-5472.can-07-0750;
RA   Balasenthil S., Gururaj A.E., Talukder A.H., Bagheri-Yarmand R.,
RA   Arrington T., Haas B.J., Braisted J.C., Kim I., Lee N.H., Kumar R.;
RT   "Identification of Pax5 as a target of MTA1 in B-cell lymphomas.";
RL   Cancer Res. 67:7132-7138(2007).
RN   [17]
RP   ERRATUM OF PUBMED:17671180.
RX   PubMed=25948590; DOI=10.1158/0008-5472.can-15-1095;
RA   Balasenthil S., Gururaj A.E., Talukder A.H., Bagheri-Yarmand R.,
RA   Arrington T., Haas B.J., Braisted J.C., Kim I., Lee N.H., Kumar R.;
RL   Cancer Res. 75:2580-2581(2015).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-386, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [20]
RP   FUNCTION.
RX   PubMed=17922032; DOI=10.1038/sj.onc.1210839;
RA   Molli P.R., Singh R.R., Lee S.W., Kumar R.;
RT   "MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene.";
RL   Oncogene 27:1971-1980(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-386; SER-449; SER-522;
RP   THR-564 AND SER-576, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH MDM2 AND TP53.
RX   PubMed=19837670; DOI=10.1074/jbc.m109.056499;
RA   Li D.Q., Divijendra Natha Reddy S., Pakala S.B., Wu X., Zhang Y.,
RA   Rayala S.K., Kumar R.;
RT   "MTA1 coregulator regulates p53 stability and function.";
RL   J. Biol. Chem. 284:34545-34552(2009).
RN   [24]
RP   UBIQUITINATION AT LYS-182 AND LYS-626, ACETYLATION AT LYS-626, MUTAGENESIS
RP   OF LYS-182 AND LYS-626, AND INTERACTION WITH COP1 AND HDAC2.
RX   PubMed=19805145; DOI=10.1073/pnas.0908027106;
RA   Li D.Q., Ohshiro K., Reddy S.D., Pakala S.B., Lee M.H., Zhang Y.,
RA   Rayala S.K., Kumar R.;
RT   "E3 ubiquitin ligase COP1 regulates the stability and functions of MTA1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:17493-17498(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-386; SER-522; THR-564;
RP   SER-576 AND THR-578, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [26]
RP   INTERACTION WITH SIX3.
RX   PubMed=20682799; DOI=10.1158/0008-5472.can-10-0909;
RA   Kumar R., Balasenthil S., Manavathi B., Rayala S.K., Pakala S.B.;
RT   "Metastasis-associated protein 1 and its short form variant stimulates Wnt1
RT   transcription through promoting its derepression from Six3 corepressor.";
RL   Cancer Res. 70:6649-6658(2010).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-386; SER-446; SER-449;
RP   SER-522; SER-576 AND THR-578, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   FUNCTION, SUMOYLATION AT LYS-509, SUBCELLULAR LOCATION (ISOFORM LONG),
RP   INTERACTION WITH HDAC2; UBE2I; PIAS1; PIAS3; PIAS4; SUMO1; SUMO2; SENP1 AND
RP   SENP2, SUMO INTERACTION MOTIF, AND MUTAGENESIS OF LYS-509 AND
RP   711-ILE--ILE-713.
RX   PubMed=21965678; DOI=10.1074/jbc.m111.267237;
RA   Cong L., Pakala S.B., Ohshiro K., Li D.Q., Kumar R.;
RT   "SUMOylation and SUMO-interacting motif (SIM) of metastasis tumor antigen 1
RT   (MTA1) synergistically regulate its transcriptional repressor function.";
RL   J. Biol. Chem. 286:43793-43808(2011).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-386; SER-446; SER-449;
RP   SER-522; SER-576; THR-578 AND SER-639, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [31]
RP   REVIEW.
RX   PubMed=22253283; DOI=10.1158/0008-5472.can-11-2345;
RA   Li D.Q., Pakala S.B., Nair S.S., Eswaran J., Kumar R.;
RT   "Metastasis-associated protein 1/nucleosome remodeling and histone
RT   deacetylase complex in cancer.";
RL   Cancer Res. 72:387-394(2012).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-386; SER-449; SER-522;
RP   THR-564 AND SER-576, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [33]
RP   INTERACTION WITH NACC2.
RX   PubMed=22926524; DOI=10.1038/onc.2012.386;
RA   Xuan C., Wang Q., Han X., Duan Y., Li L., Shi L., Wang Y., Shan L., Yao Z.,
RA   Shang Y.;
RT   "RBB, a novel transcription repressor, represses the transcription of HDM2
RT   oncogene.";
RL   Oncogene 32:3711-3721(2013).
RN   [34]
RP   FUNCTION, INTERACTION WITH TFAP2C AND IFI16, SUBCELLULAR LOCATION, AND
RP   INVOLVEMENT IN BREAST CANCER.
RX   PubMed=24413532; DOI=10.1158/0008-5472.can-13-2020;
RA   Kang H.J., Lee M.H., Kang H.L., Kim S.H., Ahn J.R., Na H., Na T.Y.,
RA   Kim Y.N., Seong J.K., Lee M.O.;
RT   "Differential regulation of estrogen receptor alpha expression in breast
RT   cancer cells by metastasis-associated protein 1.";
RL   Cancer Res. 74:1484-1494(2014).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [36]
RP   SUBCELLULAR LOCATION (ISOFORM LONG), TISSUE SPECIFICITY, AND INTERACTION
RP   WITH TPR AND HDAC2.
RX   PubMed=24970816; DOI=10.18632/oncotarget.2095;
RA   Liu J., Xu D., Wang H., Zhang Y., Chang Y., Zhang J., Wang J., Li C.,
RA   Liu H., Zhao M., Lin C., Zhan Q., Huang C., Qian H.;
RT   "The subcellular distribution and function of MTA1 in cancer
RT   differentiation.";
RL   Oncotarget 5:5153-5164(2014).
RN   [37]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-549, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [38]
RP   FUNCTION, IDENTIFICATION IN THE NURD COMPLEX, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND SUBCELLULAR LOCATION.
RX   PubMed=28977666; DOI=10.1093/nar/gkx711;
RA   Hoffmeister H., Fuchs A., Erdel F., Pinz S., Groebner-Ferreira R.,
RA   Bruckmann A., Deutzmann R., Schwartz U., Maldonado R., Huber C.,
RA   Dendorfer A.S., Rippe K., Laengst G.;
RT   "CHD3 and CHD4 form distinct NuRD complexes with different yet overlapping
RT   functionality.";
RL   Nucleic Acids Res. 45:10534-10554(2017).
RN   [39]
RP   INTERACTION WITH PWWP2A.
RX   PubMed=30327463; DOI=10.1038/s41467-018-06665-5;
RA   Link S., Spitzer R.M.M., Sana M., Torrado M., Voelker-Albert M.C.,
RA   Keilhauer E.C., Burgold T., Puenzeler S., Low J.K.K., Lindstroem I.,
RA   Nist A., Regnard C., Stiewe T., Hendrich B., Imhof A., Mann M.,
RA   Mackay J.P., Bartkuhn M., Hake S.B.;
RT   "PWWP2A binds distinct chromatin moieties and interacts with an MTA1-
RT   specific core NuRD complex.";
RL   Nat. Commun. 9:4300-4300(2018).
RN   [40]
RP   IDENTIFICATION IN THE NURD COMPLEX, IDENTIFICATION BY MASS SPECTROMETRY,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=33283408; DOI=10.1111/febs.15650;
RA   Spruijt C.G., Graewe C., Kleinendorst S.C., Baltissen M.P.A., Vermeulen M.;
RT   "Cross-linking mass spectrometry reveals the structural topology of
RT   peripheral NuRD subunits relative to the core complex.";
RL   FEBS J. 288:3231-3245(2021).
RN   [41] {ECO:0007744|PDB:4PBY, ECO:0007744|PDB:4PBZ, ECO:0007744|PDB:4PC0}
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 670-695 IN COMPLEX WITH RBBP4,
RP   AND INTERACTION WITH RBBP4.
RX   PubMed=24920672; DOI=10.1074/jbc.m114.558940;
RA   Alqarni S.S., Murthy A., Zhang W., Przewloka M.R., Silva A.P., Watson A.A.,
RA   Lejon S., Pei X.Y., Smits A.H., Kloet S.L., Wang H., Shepherd N.E.,
RA   Stokes P.H., Blobel G.A., Vermeulen M., Glover D.M., Mackay J.P.,
RA   Laue E.D.;
RT   "Insight into the architecture of the NuRD complex: structure of the
RT   RbAp48-MTA1 subcomplex.";
RL   J. Biol. Chem. 289:21844-21855(2014).
CC   -!- FUNCTION: Transcriptional coregulator which can act as both a
CC       transcriptional corepressor and coactivator (PubMed:16617102,
CC       PubMed:17671180, PubMed:17922032, PubMed:21965678, PubMed:24413532).
CC       Acts as a component of the histone deacetylase NuRD complex which
CC       participates in the remodeling of chromatin (PubMed:16428440,
CC       PubMed:28977666). In the NuRD complex, regulates transcription of its
CC       targets by modifying the acetylation status of the target chromatin and
CC       cofactor accessibility to the target DNA (PubMed:17671180). In
CC       conjunction with other components of NuRD, acts as a transcriptional
CC       corepressor of BRCA1, ESR1, TFF1 and CDKN1A (PubMed:17922032,
CC       PubMed:24413532). Acts as a transcriptional coactivator of BCAS3, and
CC       SUMO2, independent of the NuRD complex (PubMed:21965678,
CC       PubMed:17671180, PubMed:16617102). Stimulates the expression of WNT1 by
CC       inhibiting the expression of its transcriptional corepressor SIX3 (By
CC       similarity). Regulates p53-dependent and -independent DNA repair
CC       processes following genotoxic stress (PubMed:19837670). Regulates the
CC       stability and function of p53/TP53 by inhibiting its ubiquitination by
CC       COP1 and MDM2 thereby regulating the p53-dependent DNA repair
CC       (PubMed:19837670). Plays a role in the regulation of the circadian
CC       clock and is essential for the generation and maintenance of circadian
CC       rhythms under constant light and for normal entrainment of behavior to
CC       light-dark (LD) cycles (By similarity). Positively regulates the CLOCK-
CC       BMAL1 heterodimer mediated transcriptional activation of its own
CC       transcription and the transcription of CRY1 (By similarity). Regulates
CC       deacetylation of BMAL1 by regulating SIRT1 expression, resulting in
CC       derepressing CRY1-mediated transcription repression (By similarity).
CC       With TFCP2L1, promotes establishment and maintenance of pluripotency in
CC       embryonic stem cells (ESCs) and inhibits endoderm differentiation (By
CC       similarity). {ECO:0000250|UniProtKB:Q8K4B0,
CC       ECO:0000269|PubMed:16428440, ECO:0000269|PubMed:16617102,
CC       ECO:0000269|PubMed:17671180, ECO:0000269|PubMed:17922032,
CC       ECO:0000269|PubMed:19837670, ECO:0000269|PubMed:21965678,
CC       ECO:0000269|PubMed:24413532}.
CC   -!- FUNCTION: [Isoform Short]: Binds to ESR1 and sequesters it in the
CC       cytoplasm and enhances its non-genomic responses.
CC       {ECO:0000269|PubMed:15077195}.
CC   -!- SUBUNIT: Component of the nucleosome remodeling and deacetylase (NuRD)
CC       repressor complex, composed of core proteins MTA1, MTA2, MTA3, RBBP4,
CC       RBBP7, HDAC1, HDAC2, MBD2, MBD3, and peripherally associated proteins
CC       CDK2AP1, CDK2AP2, GATAD2A, GATAD2B, CHD3, CHD4 and CHD5
CC       (PubMed:33283408, PubMed:9885572, PubMed:28977666, PubMed:16428440).
CC       The exact stoichiometry of the NuRD complex is unknown, and some
CC       subunits such as MBD2 and MBD3, GATAD2A and GATAD2B, and CHD3, CHD4 and
CC       CHD5 define mutually exclusive NuRD complexes (PubMed:33283408,
CC       PubMed:16428440, PubMed:28977666). Interacts with RBBP4; the
CC       interaction is direct (PubMed:24920672). Interacts with BMAL1 (By
CC       similarity). Interacts with CLOCK (By similarity). Interacts with COP1
CC       (PubMed:19805145). Interacts with CSNK1G2 in the cytoplasm
CC       (PubMed:15077195). Interacts with EP300 (PubMed:16617102). Interacts
CC       with HDAC2 (PubMed:17671180, PubMed:19805145, PubMed:21965678,
CC       PubMed:24970816). Interacts with IFI16 (PubMed:24413532). Interacts
CC       with ITGB3BP/CENPR (PubMed:15254226). Interacts with MBD3L2
CC       (PubMed:15701600). Interacts with MDM2 (PubMed:19837670). Interacts
CC       with NACC2 (PubMed:22926524). Interacts with p53/TP53
CC       (PubMed:19837670). Interacts with PIAS1 (PubMed:21965678). Interacts
CC       with PIAS3 (PubMed:21965678). Interacts with PIAS4 (PubMed:21965678).
CC       Interacts with PWWP2A (PubMed:30327463). Interacts with PWWP2B (By
CC       similarity). Interacts with SENP1 (PubMed:21965678). Interacts with
CC       SENP2 (PubMed:21965678). Interacts with SIX3; facilitates the binding
CC       of SIX3 to the core DNA motif of SIX3 promoter (PubMed:20682799).
CC       Interacts with SUMO1 (PubMed:21965678). Interacts with SUMO2
CC       (PubMed:21965678). Interacts with TFCP2L1; which is indispensable for
CC       TFCP2L1-mediated self-renewal-promoting effect and endoderm-inhibiting
CC       action (By similarity). Interacts with TFAP2C (PubMed:24413532).
CC       Interacts with TPR (PubMed:24970816). Interacts with UBE2I/UBC9
CC       (PubMed:21965678). {ECO:0000250|UniProtKB:Q8K4B0,
CC       ECO:0000269|PubMed:15077195, ECO:0000269|PubMed:15254226,
CC       ECO:0000269|PubMed:15701600, ECO:0000269|PubMed:16428440,
CC       ECO:0000269|PubMed:16617102, ECO:0000269|PubMed:17671180,
CC       ECO:0000269|PubMed:19805145, ECO:0000269|PubMed:19837670,
CC       ECO:0000269|PubMed:20682799, ECO:0000269|PubMed:21965678,
CC       ECO:0000269|PubMed:22926524, ECO:0000269|PubMed:24413532,
CC       ECO:0000269|PubMed:24970816, ECO:0000269|PubMed:28977666,
CC       ECO:0000269|PubMed:30327463, ECO:0000269|PubMed:33283408,
CC       ECO:0000269|PubMed:9885572}.
CC   -!- INTERACTION:
CC       Q13330; Q8N726: CDKN2A; NbExp=2; IntAct=EBI-714236, EBI-625922;
CC       Q13330; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-714236, EBI-3867333;
CC       Q13330; Q96KQ7: EHMT2; NbExp=9; IntAct=EBI-714236, EBI-744366;
CC       Q13330; Q13547: HDAC1; NbExp=12; IntAct=EBI-714236, EBI-301834;
CC       Q13330; Q92769: HDAC2; NbExp=6; IntAct=EBI-714236, EBI-301821;
CC       Q13330; Q16665: HIF1A; NbExp=6; IntAct=EBI-714236, EBI-447269;
CC       Q13330; Q13422: IKZF1; NbExp=3; IntAct=EBI-714236, EBI-745305;
CC       Q13330; P05412: JUN; NbExp=4; IntAct=EBI-714236, EBI-852823;
CC       Q13330; Q5VWX1: KHDRBS2; NbExp=3; IntAct=EBI-714236, EBI-742808;
CC       Q13330; O00505: KPNA3; NbExp=3; IntAct=EBI-714236, EBI-358297;
CC       Q13330; O00629: KPNA4; NbExp=4; IntAct=EBI-714236, EBI-396343;
CC       Q13330; Q15323: KRT31; NbExp=3; IntAct=EBI-714236, EBI-948001;
CC       Q13330; Q6A162: KRT40; NbExp=4; IntAct=EBI-714236, EBI-10171697;
CC       Q13330; P60410: KRTAP10-8; NbExp=3; IntAct=EBI-714236, EBI-10171774;
CC       Q13330; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-714236, EBI-741037;
CC       Q13330; P43364-2: MAGEA11; NbExp=3; IntAct=EBI-714236, EBI-10178634;
CC       Q13330; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-714236, EBI-945833;
CC       Q13330; P0DPK4: NOTCH2NLC; NbExp=3; IntAct=EBI-714236, EBI-22310682;
CC       Q13330; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-714236, EBI-79165;
CC       Q13330; Q58EX7: PLEKHG4; NbExp=3; IntAct=EBI-714236, EBI-949255;
CC       Q13330; Q09028: RBBP4; NbExp=10; IntAct=EBI-714236, EBI-620823;
CC       Q13330; P21673: SAT1; NbExp=3; IntAct=EBI-714236, EBI-711613;
CC       Q13330; Q6FGM0: SH3GL1; NbExp=3; IntAct=EBI-714236, EBI-10173690;
CC       Q13330; Q99961: SH3GL1; NbExp=3; IntAct=EBI-714236, EBI-697911;
CC       Q13330; O60315: ZEB2; NbExp=12; IntAct=EBI-714236, EBI-717614;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:24413532,
CC       ECO:0000269|PubMed:28977666, ECO:0000269|PubMed:33283408}.
CC   -!- SUBCELLULAR LOCATION: [Isoform Short]: Cytoplasm
CC       {ECO:0000269|PubMed:12167865, ECO:0000269|PubMed:15077195}.
CC   -!- SUBCELLULAR LOCATION: [Isoform Long]: Nucleus
CC       {ECO:0000269|PubMed:21965678}. Nucleus envelope
CC       {ECO:0000269|PubMed:24970816}. Cytoplasm {ECO:0000269|PubMed:16617102,
CC       ECO:0000269|PubMed:24970816}. Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:24970816}. Note=Associated with microtubules
CC       (PubMed:24970816). Localization at the nuclear envelope is TPR-
CC       dependent (PubMed:24970816). {ECO:0000269|PubMed:24970816}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=Long;
CC         IsoId=Q13330-1; Sequence=Displayed;
CC       Name=Short; Synonyms=MTA1S;
CC         IsoId=Q13330-2; Sequence=VSP_001601, VSP_001602;
CC       Name=3;
CC         IsoId=Q13330-3; Sequence=VSP_042207;
CC   -!- TISSUE SPECIFICITY: Widely expressed. High expression in brain, liver,
CC       kidney, and cardiac muscle, ovaries, adrenal glands and virgin mammary
CC       glands. Higher in tumors than in adjacent normal tissue from the same
CC       individual. Up-regulated in a wide variety of cancers including breast,
CC       liver, ovarian, and colorectal cancer and its expression levels are
CC       closely correlated with tumor aggressiveness and metastasis.
CC       {ECO:0000269|PubMed:16617102, ECO:0000269|PubMed:24970816}.
CC   -!- DEVELOPMENTAL STAGE: Highly expressed in metastatic cells.
CC   -!- DOMAIN: Isoform Short contains a Leu-Arg-Ile-Leu-Leu motif (ER binding
CC       motif).
CC   -!- PTM: Phosphorylation by CSNK1G2/CK1 triggered by estrogen enhances
CC       corepression of estrogen receptor (ER). {ECO:0000269|PubMed:15077195}.
CC   -!- PTM: Acetylation is essential for its transcriptional coactivator
CC       activity. {ECO:0000269|PubMed:16617102, ECO:0000269|PubMed:17671180,
CC       ECO:0000269|PubMed:19805145}.
CC   -!- PTM: Sumoylation positively regulates its transcriptional corepressor
CC       activity but does not affect the protein stability. Sumoylated
CC       preferentially by SUMO2 or SUMO3 than SUMO1. Sumoylation is enhanced by
CC       PIAS1/3/4 and preferentially sumoylated by SUMO2 in the presence of
CC       PIAS1/3/4. Desumoylated by SENP1. {ECO:0000269|PubMed:21965678}.
CC   -!- PTM: Ubiquitinated by COP1, which leads to proteasomal degradation.
CC       {ECO:0000269|PubMed:19805145}.
CC   -!- DISEASE: Note=Involved in the epigenetic regulation of ESR1 expression
CC       in breast cancer in a TFAP2C, IFI16 and HDAC4/5/6-dependent manner.
CC       {ECO:0000269|PubMed:24413532}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/41443/mta1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U35113; AAA78935.1; -; mRNA.
DR   EMBL; AF508978; AAN01613.1; -; mRNA.
DR   EMBL; AL928654; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC009443; AAH09443.2; -; mRNA.
DR   EMBL; BC142941; AAI42942.1; -; mRNA.
DR   EMBL; BX248776; CAD66583.1; -; mRNA.
DR   CCDS; CCDS32169.1; -. [Q13330-1]
DR   CCDS; CCDS55954.1; -. [Q13330-2]
DR   CCDS; CCDS91957.1; -. [Q13330-3]
DR   RefSeq; NP_001190187.1; NM_001203258.1. [Q13330-2]
DR   RefSeq; NP_004680.2; NM_004689.3. [Q13330-1]
DR   PDB; 4BKX; X-ray; 3.00 A; A=162-335.
DR   PDB; 4PBY; X-ray; 2.50 A; C/D=656-686.
DR   PDB; 4PBZ; X-ray; 2.15 A; B=670-695.
DR   PDB; 4PC0; X-ray; 2.50 A; C/D=670-711.
DR   PDB; 5FXY; X-ray; 3.20 A; B/D/F/H=464-546.
DR   PDB; 5ICN; X-ray; 3.30 A; A=162-354.
DR   PDB; 6G16; X-ray; 2.80 A; B/D/F/H=464-546.
DR   PDB; 6ZRC; X-ray; 2.60 A; P/Q=677-689.
DR   PDB; 6ZRD; X-ray; 2.50 A; P/Q=677-689.
DR   PDB; 7AO8; EM; 4.50 A; A/D=1-715.
DR   PDB; 7AO9; EM; 6.10 A; A/D=1-715.
DR   PDB; 7AOA; EM; 19.40 A; A/D=1-715.
DR   PDBsum; 4BKX; -.
DR   PDBsum; 4PBY; -.
DR   PDBsum; 4PBZ; -.
DR   PDBsum; 4PC0; -.
DR   PDBsum; 5FXY; -.
DR   PDBsum; 5ICN; -.
DR   PDBsum; 6G16; -.
DR   PDBsum; 6ZRC; -.
DR   PDBsum; 6ZRD; -.
DR   PDBsum; 7AO8; -.
DR   PDBsum; 7AO9; -.
DR   PDBsum; 7AOA; -.
DR   AlphaFoldDB; Q13330; -.
DR   SMR; Q13330; -.
DR   BioGRID; 114562; 272.
DR   ComplexPortal; CPX-880; MBD2/NuRD nucleosome remodeling and deacetylase complex.
DR   ComplexPortal; CPX-922; MBD3/NuRD nucleosome remodeling and deacetylase complex.
DR   CORUM; Q13330; -.
DR   DIP; DIP-41751N; -.
DR   IntAct; Q13330; 101.
DR   MINT; Q13330; -.
DR   STRING; 9606.ENSP00000333633; -.
DR   GlyCosmos; Q13330; 1 site, 1 glycan.
DR   GlyGen; Q13330; 4 sites, 1 O-linked glycan (4 sites).
DR   iPTMnet; Q13330; -.
DR   PhosphoSitePlus; Q13330; -.
DR   SwissPalm; Q13330; -.
DR   BioMuta; MTA1; -.
DR   DMDM; 259016275; -.
DR   CPTAC; CPTAC-1619; -.
DR   EPD; Q13330; -.
DR   jPOST; Q13330; -.
DR   MassIVE; Q13330; -.
DR   MaxQB; Q13330; -.
DR   PaxDb; Q13330; -.
DR   PeptideAtlas; Q13330; -.
DR   ProteomicsDB; 59317; -. [Q13330-1]
DR   ProteomicsDB; 59318; -. [Q13330-2]
DR   ProteomicsDB; 59319; -. [Q13330-3]
DR   ABCD; Q13330; 1 sequenced antibody.
DR   Antibodypedia; 90; 468 antibodies from 37 providers.
DR   DNASU; 9112; -.
DR   Ensembl; ENST00000331320.12; ENSP00000333633.7; ENSG00000182979.18. [Q13330-1]
DR   Ensembl; ENST00000405646.5; ENSP00000384180.1; ENSG00000182979.18. [Q13330-3]
DR   Ensembl; ENST00000438610.5; ENSP00000393438.1; ENSG00000182979.18. [Q13330-2]
DR   GeneID; 9112; -.
DR   KEGG; hsa:9112; -.
DR   MANE-Select; ENST00000331320.12; ENSP00000333633.7; NM_004689.4; NP_004680.2.
DR   UCSC; uc001yqx.4; human. [Q13330-1]
DR   AGR; HGNC:7410; -.
DR   CTD; 9112; -.
DR   DisGeNET; 9112; -.
DR   GeneCards; MTA1; -.
DR   HGNC; HGNC:7410; MTA1.
DR   HPA; ENSG00000182979; Low tissue specificity.
DR   MIM; 603526; gene.
DR   neXtProt; NX_Q13330; -.
DR   OpenTargets; ENSG00000182979; -.
DR   PharmGKB; PA31218; -.
DR   VEuPathDB; HostDB:ENSG00000182979; -.
DR   eggNOG; KOG3554; Eukaryota.
DR   GeneTree; ENSGT01030000234573; -.
DR   HOGENOM; CLU_006585_2_1_1; -.
DR   InParanoid; Q13330; -.
DR   OMA; HEWLILT; -.
DR   OrthoDB; 12566at2759; -.
DR   PhylomeDB; Q13330; -.
DR   TreeFam; TF106444; -.
DR   PathwayCommons; Q13330; -.
DR   Reactome; R-HSA-3214815; HDACs deacetylate histones.
DR   Reactome; R-HSA-3232118; SUMOylation of transcription factors.
DR   Reactome; R-HSA-427389; ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression.
DR   Reactome; R-HSA-73762; RNA Polymerase I Transcription Initiation.
DR   Reactome; R-HSA-8943724; Regulation of PTEN gene transcription.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   SignaLink; Q13330; -.
DR   SIGNOR; Q13330; -.
DR   BioGRID-ORCS; 9112; 19 hits in 1177 CRISPR screens.
DR   ChiTaRS; MTA1; human.
DR   GeneWiki; MTA1; -.
DR   GenomeRNAi; 9112; -.
DR   Pharos; Q13330; Tbio.
DR   PRO; PR:Q13330; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; Q13330; protein.
DR   Bgee; ENSG00000182979; Expressed in right uterine tube and 203 other tissues.
DR   ExpressionAtlas; Q13330; baseline and differential.
DR   Genevisible; Q13330; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005874; C:microtubule; IDA:UniProtKB.
DR   GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016581; C:NuRD complex; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IEA:InterPro.
DR   GO; GO:0042826; F:histone deacetylase binding; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0003713; F:transcription coactivator activity; IMP:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; IMP:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; IDA:ComplexPortal.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0006302; P:double-strand break repair; IMP:UniProtKB.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0040029; P:epigenetic regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0016575; P:histone deacetylation; IDA:ComplexPortal.
DR   GO; GO:0045475; P:locomotor rhythm; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; NAS:ComplexPortal.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; NAS:ComplexPortal.
DR   GO; GO:1902499; P:positive regulation of protein autoubiquitination; IDA:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0042659; P:regulation of cell fate specification; NAS:ComplexPortal.
DR   GO; GO:2000736; P:regulation of stem cell differentiation; NAS:ComplexPortal.
DR   GO; GO:0010212; P:response to ionizing radiation; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   CDD; cd04709; BAH_MTA; 1.
DR   CDD; cd11661; SANT_MTA3_like; 1.
DR   CDD; cd00202; ZnF_GATA; 1.
DR   Gene3D; 2.30.30.490; -; 1.
DR   Gene3D; 4.10.1240.50; -; 1.
DR   Gene3D; 1.10.10.60; Homeodomain-like; 1.
DR   IDEAL; IID00563; -.
DR   InterPro; IPR001025; BAH_dom.
DR   InterPro; IPR043151; BAH_sf.
DR   InterPro; IPR000949; ELM2_dom.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR040138; MIER/MTA.
DR   InterPro; IPR035170; MTA1_R1.
DR   InterPro; IPR001005; SANT/Myb.
DR   InterPro; IPR017884; SANT_dom.
DR   InterPro; IPR000679; Znf_GATA.
DR   PANTHER; PTHR10865; METASTASIS-ASSOCIATED PROTEIN AND MESODERM INDUCTION EARLY RESPONSE PROTEIN; 1.
DR   PANTHER; PTHR10865:SF5; METASTASIS-ASSOCIATED PROTEIN MTA1; 1.
DR   Pfam; PF01426; BAH; 1.
DR   Pfam; PF01448; ELM2; 1.
DR   Pfam; PF00320; GATA; 1.
DR   Pfam; PF17226; MTA_R1; 2.
DR   Pfam; PF00249; Myb_DNA-binding; 1.
DR   SMART; SM00439; BAH; 1.
DR   SMART; SM01189; ELM2; 1.
DR   SMART; SM00717; SANT; 1.
DR   SMART; SM00401; ZnF_GATA; 1.
DR   SUPFAM; SSF46689; Homeodomain-like; 1.
DR   PROSITE; PS51038; BAH; 1.
DR   PROSITE; PS51156; ELM2; 1.
DR   PROSITE; PS51293; SANT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   Biological rhythms; Cytoplasm; Cytoskeleton; DNA-binding; Isopeptide bond;
KW   Metal-binding; Nucleus; Phosphoprotein; Reference proteome; Repressor;
KW   Transcription; Transcription regulation; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..715
FT                   /note="Metastasis-associated protein MTA1"
FT                   /id="PRO_0000083493"
FT   DOMAIN          1..164
FT                   /note="BAH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00370"
FT   DOMAIN          165..276
FT                   /note="ELM2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00512"
FT   DOMAIN          283..335
FT                   /note="SANT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00624"
FT   ZN_FING         393..420
FT                   /note="GATA-type; atypical"
FT   REGION          435..460
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          656..686
FT                   /note="Interaction with RBBP4"
FT                   /evidence="ECO:0000269|PubMed:24920672"
FT   REGION          673..715
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           545..552
FT                   /note="SH3-binding"
FT                   /evidence="ECO:0000255"
FT   MOTIF           696..705
FT                   /note="SH3-binding"
FT                   /evidence="ECO:0000255"
FT   MOTIF           711..715
FT                   /note="SUMO interaction motif 1 (SIM); crucial for
FT                   efficient sumoylation"
FT   COMPBIAS        694..708
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         386
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         446
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         449
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         522
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         564
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         576
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         578
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692"
FT   MOD_RES         626
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:16617102,
FT                   ECO:0000269|PubMed:17671180, ECO:0000269|PubMed:19805145"
FT   MOD_RES         639
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   CROSSLNK        182
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:19805145"
FT   CROSSLNK        509
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2 and SUMO3)"
FT   CROSSLNK        549
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        626
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000269|PubMed:19805145"
FT   VAR_SEQ         64..81
FT                   /note="TLSVCYKAGPGADNGEEG -> R (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_042207"
FT   VAR_SEQ         398..430
FT                   /note="TTQSYQWYSWGPPNMQCRLCASCWTYWKKYGGL -> MSSLRILLDILEEIW
FT                   WLENANPVRWREARTKPQ (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:12167865"
FT                   /id="VSP_001601"
FT   VAR_SEQ         431..715
FT                   /note="Missing (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:12167865"
FT                   /id="VSP_001602"
FT   VARIANT         372
FT                   /note="V -> I (in dbSNP:rs4983413)"
FT                   /id="VAR_055847"
FT   VARIANT         612
FT                   /note="A -> T (in dbSNP:rs13707)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:7607577, ECO:0000269|PubMed:8083195"
FT                   /id="VAR_058965"
FT   MUTAGEN         182
FT                   /note="K->A: Reduced ubiquitination. Significant reduction
FT                   in ubiquitination; when associated with A-626."
FT                   /evidence="ECO:0000269|PubMed:19805145"
FT   MUTAGEN         509
FT                   /note="K->R: Reduced sumoylation and transcriptional
FT                   corepressor activity."
FT                   /evidence="ECO:0000269|PubMed:21965678"
FT   MUTAGEN         626
FT                   /note="K->A: Loss of acetylation and transcriptional
FT                   coactivator activity. Reduced ubiquitination. Significant
FT                   reduction in ubiquitination; when associated with A-182."
FT                   /evidence="ECO:0000269|PubMed:16617102,
FT                   ECO:0000269|PubMed:17671180, ECO:0000269|PubMed:19805145"
FT   MUTAGEN         711..713
FT                   /note="IVI->AAA: Significant loss of interaction with SUMO1
FT                   and SUMO2 and reduced transcriptional corepressor
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:21965678"
FT   CONFLICT        498
FT                   /note="H -> N (in Ref. 1; AAA78935)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        545
FT                   /note="P -> R (in Ref. 5; AAI42942)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        655
FT                   /note="D -> G (in Ref. 1; AAA78935)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        661..662
FT                   /note="AT -> PK (in Ref. 1; AAA78935)"
FT                   /evidence="ECO:0000305"
FT   TURN            171..173
FT                   /evidence="ECO:0007829|PDB:4BKX"
FT   TURN            192..194
FT                   /evidence="ECO:0007829|PDB:4BKX"
FT   STRAND          195..199
FT                   /evidence="ECO:0007829|PDB:4BKX"
FT   HELIX           207..224
FT                   /evidence="ECO:0007829|PDB:4BKX"
FT   HELIX           238..246
FT                   /evidence="ECO:0007829|PDB:4BKX"
FT   HELIX           248..260
FT                   /evidence="ECO:0007829|PDB:4BKX"
FT   TURN            261..263
FT                   /evidence="ECO:0007829|PDB:4BKX"
FT   HELIX           265..272
FT                   /evidence="ECO:0007829|PDB:4BKX"
FT   HELIX           284..287
FT                   /evidence="ECO:0007829|PDB:4BKX"
FT   HELIX           290..303
FT                   /evidence="ECO:0007829|PDB:4BKX"
FT   HELIX           307..313
FT                   /evidence="ECO:0007829|PDB:4BKX"
FT   HELIX           320..330
FT                   /evidence="ECO:0007829|PDB:4BKX"
FT   STRAND          472..474
FT                   /evidence="ECO:0007829|PDB:6G16"
FT   HELIX           477..485
FT                   /evidence="ECO:0007829|PDB:6G16"
FT   HELIX           487..490
FT                   /evidence="ECO:0007829|PDB:6G16"
FT   HELIX           492..495
FT                   /evidence="ECO:0007829|PDB:6G16"
FT   HELIX           505..514
FT                   /evidence="ECO:0007829|PDB:6G16"
FT   HELIX           534..542
FT                   /evidence="ECO:0007829|PDB:6G16"
FT   HELIX           674..680
FT                   /evidence="ECO:0007829|PDB:4PBZ"
SQ   SEQUENCE   715 AA;  80786 MW;  2D5330F0489AE62E CRC64;
     MAANMYRVGD YVYFENSSSN PYLIRRIEEL NKTANGNVEA KVVCFYRRRD ISSTLIALAD
     KHATLSVCYK AGPGADNGEE GEIEEEMENP EMVDLPEKLK HQLRHRELFL SRQLESLPAT
     HIRGKCSVTL LNETESLKSY LEREDFFFYS LVYDPQQKTL LADKGEIRVG NRYQADITDL
     LKEGEEDGRD QSRLETQVWE AHNPLTDKQI DQFLVVARSV GTFARALDCS SSVRQPSLHM
     SAAAASRDIT LFHAMDTLHK NIYDISKAIS ALVPQGGPVL CRDEMEEWSA SEANLFEEAL
     EKYGKDFTDI QQDFLPWKSL TSIIEYYYMW KTTDRYVQQK RLKAAEAESK LKQVYIPNYN
     KPNPNQISVN NVKAGVVNGT GAPGQSPGAG RACESCYTTQ SYQWYSWGPP NMQCRLCASC
     WTYWKKYGGL KMPTRLDGER PGPNRSNMSP HGLPARSSGS PKFAMKTRQA FYLHTTKLTR
     IARRLCREIL RPWHAARHPY LPINSAAIKA ECTARLPEAS QSPLVLKQAV RKPLEAVLRY
     LETHPRPPKP DPVKSVSSVL SSLTPAKVAP VINNGSPTIL GKRSYEQHNG VDGNMKKRLL
     MPSRGLANHG QARHMGPSRN LLLNGKSYPT KVRLIRGGSL PPVKRRRMNW IDAPDDVFYM
     ATEETRKIRK LLSSSETKRA ARRPYKPIAL RQSQALPPRP PPPAPVNDEP IVIED
//
